Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582018 · ClinicalTrials.gov registry record · NA
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
A NA study, sponsored by Techsomed Medical Technologies.
- Terminated
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT05582018 is a NA study that was terminated before completion, run by Techsomed Medical Technologies. The registered enrollment target is 4 participants.
The verdict
NCT05582018, a NA study, was terminated before completion, sponsored by Techsomed Medical Technologies.
- TERMINATED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures Multi-center (up to 5 investigational sites) prospective single-arm clinical investigation. Sample size - 30 subjects.
Interventions
- DEVICE BioTraceIO 360
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2023-09-05 |
| Est. Completion | 2024-05-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05582018
The ClinicalTrials.gov registry entry for NCT05582018 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Techsomed Medical Technologies, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BioTraceIO 360 is the first listed.
NCT05582018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05582018 about?
NCT05582018 is a clinical study titled "Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures". Pilot study planned to demonstrate the safety and effectiveness of the use of BioTraceIO 360 for Planning, Monitoring and Assessment of liver tissue ablation procedures Multi-center (up to 5 investigational sites) prospective single-arm clinical investigation. Sample size - 30 subjects.
What is the current status of trial NCT05582018?
This trial is currently terminated. It is a NA study. The enrollment target is 4 participants. The study started on 2023-09-05. Estimated completion is 2024-05-15.
What interventions are being tested in trial NCT05582018?
The interventions under investigation include: BioTraceIO 360 (DEVICE).
Who is sponsoring clinical trial NCT05582018?
This trial is sponsored by Techsomed Medical Technologies, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.